HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Matthew Frankel Selected Research

visilizumab

11/2010Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis.
11/2007A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Matthew Frankel Research Topics

Disease

2Infections
01/2016 - 12/2015
2Ulcerative Colitis
11/2010 - 11/2007
1Turner Syndrome (Turner's Syndrome)
12/2014
1Heart Diseases (Heart Disease)
11/2010
1Uterine Cervical Neoplasms (Cancer of the Cervix)
10/2008

Drug/Important Bio-Agent (IBA)

2RNA (Ribonucleic Acid)IBA
01/2016 - 12/2015
2AntibodiesIBA
01/2016 - 12/2015
2visilizumabIBA
11/2010 - 11/2007
2Adrenal Cortex Hormones (Corticosteroids)IBA
11/2010 - 11/2007
2Monoclonal AntibodiesIBA
11/2010 - 11/2007
1Glycoproteins (Glycoprotein)IBA
01/2016
1Proteins (Proteins, Gene)FDA Link
01/2016
1Human Growth Hormone (Saizen)FDA LinkGeneric
12/2014
1Growth Hormone (Somatotropin)IBA
12/2014
1Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
10/2008
1Biological ProductsIBA
11/2007
1SteroidsIBA
11/2007